Overview

  • Product nameAnti-Cytokeratin 5 antibody [EPR1600Y]
    See all Cytokeratin 5 primary antibodies
  • Description
    Rabbit monoclonal [EPR1600Y] to Cytokeratin 5
  • Tested applicationsSuitable for: IHC-Fr, WB, IHC-P, ICC/IF, Flow Cytmore details
    Unsuitable for: IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human Cytokeratin 5.
    Database link: P13647

  • Positive control
    • A431 cell lysate and human squamous cervical carcinoma tissue.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated ‘PUR’ on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Alternative versions available:

    Anti-Cytokeratin 5 antibody (Alexa Fluor® 488) [EPR1600Y] (ab207351)

    Anti-Cytokeratin 5 antibody (Alexa Fluor® 647) [EPR1600Y] (ab207352)

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
  • Dissociation constant (KD) KD = 3.19 x 10 -10 M Learn more about KD
  • Storage bufferpH: 7.20
    Preservative: 0.01% Sodium azide
    Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
  • Concentration information loading...
  • PurityProtein A purified
  • ClonalityMonoclonal
  • Clone numberEPR1600Y
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab75869 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration.
WB 1/10000 - 1/50000. Detects a band of approximately 62 kDa (predicted molecular weight: 62 kDa).
IHC-P 1/100 - 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ICC/IF 1/100 - 1/500.
Flow Cyt Use at an assay dependent concentration.
  • Application notesIs unsuitable for IP.
  • Target

    • Involvement in diseaseDefects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
      Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping.
      Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
      Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, althought it is less severe.
      Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
      Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.
    • Sequence similaritiesBelongs to the intermediate filament family.
    • Information by UniProt
    • Database links
    • Alternative names
      • 58 kDa cytokeratin antibody
      • CK-5 antibody
      • CK5 antibody
      • Cytokeratin-5 antibody
      • Cytokeratin5 antibody
      • DDD antibody
      • DDD1 antibody
      • EBS2 antibody
      • epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody
      • K2C5_HUMAN antibody
      • K5 antibody
      • keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types) antibody
      • Keratin 5 antibody
      • Keratin antibody
      • keratin complex 2, basic, gene 5 antibody
      • keratin, type II cytoskeletal 5 antibody
      • Keratin-5 antibody
      • Keratin5 antibody
      • KRT 5 antibody
      • Krt5 antibody
      • KRT5A antibody
      • type II cytoskeletal 5 antibody
      • Type-II keratin Kb5 antibody
      see all

    Anti-Cytokeratin 5 antibody [EPR1600Y] images

    • Fluorescent immunohistochemical analysis of paraffin-embedded human cervical carcinoma tissue using unpurified ab75869. Green-CK5 red-PI

    • Immunocytochemistry/Immunofluorescence analysis of A431 (human epidermoid carcinoma) cells labelling Cytokeratin 5 with purified ab75869 at 1/100. Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. The cells were co-stained with ab7291, a mouse anti-tubulin antibody (1/1000) using ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) as the secondary. Nuclei couterstained with DAPI (blue).

      For negative control 1, rabbit primary antibody was used, followed by anti-mouse secondary antibody (ab150120). For negative control 2, mouse primary antibody (ab7291) was used followed by anti-rabbit secondary antibody (ab150077).  

    • All lanes : Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869) at 1/50000 dilution (purified)

      Lane 1 : A431 (human epidermoid carcinoma) whole cell lysate
      Lane 2 : HACAT (human keratinocyte) whole cell lysate
      Lane 3 : Human skin tissue lysate
      Lane 4 : Human fetal tonsil tissue lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

      Predicted band size : 62 kDa
      Observed band size : 62 kDa
      Blocking and diluting buffer 5% NFDM/TBST
    • Flow Cytometry analysis of A431 (human epidermoid carcinoma) cells labeling Cytokeratin 5 with purified ab75869 at 1/20 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) was used as the unlabeled control.

    • Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869) at 1/10000 dilution (unpurified) + A431 cell lysate at 10 µg

      Secondary
      goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 62 kDa
      Observed band size : 62 kDa
    • Immunohistochemical analysis of paraffin embedded human tonsil tissue section labelling Cytokeratin 5 with purified ab75869 at dilution of 1/1000. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset. 

    • Unpurified ab75869 at 1/100 dilution staining Cytokeratin 5 in human squamous cervical carcinoma by Immunohistochemistry, Paraffin-embedded tissue.

    • Fluorescent immunohistochemical analysis of paraffin-embedded human cervical carcinoma using unpurified ab75869. Green-CK5 red-PI.

    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

    References for Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869)

    This product has been referenced in:
    • Brann JH  et al. Injury in aged animals robustly activates quiescent olfactory neural stem cells. Front Neurosci 9:367 (2015). Mouse . Read more (PubMed: 26500487) »
    • Pinto MP  et al. Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling. BMC Cancer 14:735 (2014). Read more (PubMed: 25274034) »

    See all 10 Publications for this product

    Product Wall

    Application Western blot
    Loading amount 30 µg
    Gel Running Conditions Reduced Denaturing (4-12%)
    Sample Human Cell lysate - whole cell (Human Breast Cancer Cell Lines)
    Specification Human Breast Cancer Cell Lines
    Blocking step Milk as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 4°C
    Username

    Abcam user community

    Verified customer

    Submitted Mar 04 2015

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"